Aducanumab: A Deep Dive into BIIB037 and its Impact A compound, initially known as BIIB037, represents a notable effort to treat emerging Alzheimer's disease. Designed by Biogen, this molecule acts by targeting amyloid https://www.targetmol.com/compound/aducanumab